Mark Fereshteh is a prominent figure in cancer research and drug discovery, currently serving as the Chief Scientific Officer at Pathos since October 2025. Prior experience includes roles at Genmab from January 2019 to October 2025, where Mark held several leadership positions, including Vice President, Global Head of Precision Medicine and Diagnostics, and oversaw translational medicine efforts. Earlier, Mark worked at Bristol-Myers Squibb for seven years in various capacities related to lead discovery in oncology. Mark's academic foundation includes a postdoctoral fellowship at Duke University, focusing on hematopoietic malignancies in renowned laboratories, and a PhD in Tumor Biology from Georgetown University, emphasizing steroid receptor coactivators in cancer.
This person is not in any teams
This person is not in any offices